AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03924778 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: standard American diet
Description: describe
Study NCT05414812 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multi-component oncofertility care intervention
Description: The intervention includes:~1. Young breast cancer patients presenting to oncology visits will complete a clinic-based oncofertility needs screen with a member of the clinical team. This needs screen assesses i) desire to have a child in the future, ii) need for contraception, and iii) sexual health/menopause symptoms.~2. A women's health survivorship care plan (SCP) in Spanish and English encompasses content on screening and management strategies for a) fertility concerns/pregnancy health; b) contraception; c) hot flashes and d) sexual health.~3. Oncofertility navigation consists of one telehealth or in-person session with a social worker to: i) assess the patient's oncofertility needs, ii) review the women's health SCP, iii) provide support with the goal of engaging in oncofertility care.~4. Oncofertility consultation as indicated via telehealth or in person will occur between the patient and reproductive specialist. Each consultation is estimated to be 1 hour.
Study NCT06572618 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT06572618 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow biopsy
Study NCT06572618 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nemtabrutinib
Description: Given PO
Study NCT06572618 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography and Computed Tomography Scan
Description: Undergo PET-CT scan
Study NCT06572618 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV
Study NCT04711356 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ad26.ZEBOV booster vaccination, given at a dose of 5x10^10 vp, via IM injection
Description: Ad26.ZEBOV is a monovalent, replication-incompetent adenovirus serotype 26-based vector that expresses the full-length Ebola virus Mayinga glycoprotein
Study NCT05580783 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test meal labelled with 54Fe
Description: Each participant will receive 2 test meals containing 4mg each of isotopic tracer 54Fe
Study NCT05580783 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test meal labelled with 57Fe
Description: Each participant will receive 2 test meals containing 4mg each of isotopic tracer 57Fe
Study NCT05580783 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test meal labelled with 58Fe
Description: Each participant will receive 2 test meals containing 4mg each of isotopic tracer 58Fe
Study NCT05985109 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KN046
Description: KN046 is a recombinant humanized PD-L1/CTLA-4 bispecific single-domain antibody that blocks both PD-L1 interaction with PD-1 and CTLA-4 interaction with CD80/CD86.
Study NCT05985109 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: regorafenib
Description: Regorafenib is a multi-target tyrosine kinase inhibitors and is one of the standard third-line therapy in mCRC
Study NCT04783987 — intervention group
Intervention type: OTHER
Intervention: Walking asessments
Description: Gait parameters will be evaluated in single and dual task conditions with 10 Meter Walk Test and wireless digital miniature portable walking and movement analyzer.
Study NCT05272787 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TH Facial Moisturizer
Description: All subjects will receive all the products. There will be a supervised application at the site on the baseline visit of the study. Then subjects will use all the products at home.
Study NCT04277611 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Subcostal Oblique Quadratus Lumborum Block and Erector Spinae Plain Block.
Description: patients undergo general anesthesia,will be put in prone position.In case of Quadratus Lumborum block 1-3 mL of normal saline is injected to produce hydro-dissection and spread cranially between the QL and kidney. The corresponding ultrasonographic sign is a lunar-shaped hypo-echoic fluid collection observed between the long axis of the kidney and QL muscle. 20 ml Bupivacaine 0.5%, 10 ml Lidocaine 2%, and 10 ml normal saline is administered. In case of the ESPB The location of the needle tip is confirmed by hydro-dissection and after visualizing the fluid spread lifting the Erector Spinae off the transverse process, 20 ml bupivacaine 0.5%, 10 ml Lidocaine 2%, and 10 ml normal saline is injected.
Study NCT04731415 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Optical coherence tomography and optical coherence tomography angiography (Optovue®)
Description: Optical coherence tomography and optical coherence tomography angiography (Optovue®) were performed in each trimesters and at 6 weeks after childbirth.~1. st trimester : gestational age 8-12 weeks~2. nd trimester : gestational age 24-28 weeks~3. rd trimester : gestational age 34-38 weeks
Study NCT06533098 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nipocalimab
Description: Nipocalimab will be administered intravenously.
Study NCT06533098 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulins (IVIG)
Description: IVIG will be administered intravenously.
Study NCT06533098 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone will be administered orally.
Study NCT06510530 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Astragalus
Description: Patients in the intervention group will receive capsules of the Astragalus plant (scientific name: Astragalus membranaceus, common name: Huang Qi) at an initial dose of 2 grams (4 capsules) per day with the option of increasing the dose to 4 grams (8 capsules) per day according to researchers' assessment and patient tolerance. The dose was determined by a focus group of 5 herbalists and according to data from the literature on oncology patients. The duration of the treatment will be up to a month from the end of the chemotherapy treatment which usually lasts up to six months.
Study NCT06510530 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules that look similar to Astragalus capsules will be given to patients from the control group, between 4 and 8 capsules per day according to the researcher's assessment and tolerability. The duration of the treatment will be up to a month from the end of the chemotherapy treatment which usually lasts up to six months.
Study NCT06486948 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CT-156
Description: CT-156 is a digital therapeutic (DTx) under development to treat patients 18 years of age and older with a diagnosis of schizophrenia under standard of care therapy who are on antipsychotic medication and not currently experiencing acute hallucinations or delusions.
Study NCT06486948 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CT-156
Description: CT-156 is a digital therapeutic (DTx) under development to treat patients 18 years of age and older with a diagnosis of schizophrenia under standard of care therapy who are on antipsychotic medication and not currently experiencing acute hallucinations or delusions.
Study NCT05418764 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Miyamodel Training
Description: standardized training by performing five hysterectomies on the Miyamodel with a trainer who is a sub-PI at each institution
Study NCT04935814 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vasopressin, Arginine
Description: Once vasopressin infusion started, patients positions will be randomized: Trendelenburg (-30°), anti Trendelenburg (+30°) and supine position (0°).
Study NCT05438186 — intervention group
Intervention type: DRUG
Intervention: Liraglutide
Description: Participants with obesity who received initial prescription of Saxenda® (liragltuide 3.0 milligrams (mg) once daily)) and maintained treatment with Saxenda® for at least 16 weeks, without treatment break, following the initial prescription for weight management.
Study NCT05272787 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TH Lip Moisturizer
Description: All subjects will receive all the products. There will be a supervised application at the site on the baseline visit of the study. Then subjects will use all the products at home.
Study NCT05272787 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Facial Moisturizer B (Control)
Description: All subjects will receive all the products. There will be a supervised application at the site on the baseline visit of the study. Then subjects will use all the products at home.
Study NCT06668727 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HepB mAb19
Description: The study has two parts:~Part A will involve administering a single ascending dose of HepB mAb19 or placebo using a randomized, double-blind method in Groups 1-3 at dose levels of 3, 10, and 30 mg/kg. Participants enrolled in Groups 1-3 will be randomized at a 3:1 ratio to receive HepB mAb19 or placebo. Part B will assess the maximum tolerated dose (MTD) in Group 4 in an openlabel fashion. Participants will receive HepB mAb19 at MTD.
Study NCT04230499 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Encapsulated Rapamycin (eRapa)
Description: eRapa is encapsulated rapamycin. The rapamycin is encapsulated in order to deliver the rapamycin at a consistent and lower dosage. eRapa is a capsule, and is administered orally.
Study NCT05272787 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sunscreen
Description: Auxiliary product
Study NCT05964855 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MIT Variable Stiffness Prosthesis
Description: Proprietary electronically-controlled prosthesis that can vary its effective stiffness.
Study NCT05964855 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MIT Variable Equilibrium Angle Prosthesis
Description: Proprietary manually-controlled prosthesis that can vary its effective ankle equilibrium angle.
Study NCT05964855 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MIT Sliding Beam Passive Prosthesis
Description: Proprietary fixed-stiffness passive foot-ankle prosthesis.
Study NCT05964855 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ossur Pro-flex XC
Description: Commercially-available passive fixed-stiffness foot-ankle prosthesis by Ossur.
Study NCT05964855 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blatchford Elan Variable-Dampening Prosthesis
Description: Commercially-available electronically-controlled prosthesis that can vary its effective dampening.
Study NCT05272787 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Facial wash
Description: Auxiliary product.
Study NCT06230614 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Colistin 1 MU in normal saline 1 ml
Description: Colistin 1 MU diluted in normal saline 1 ml, total volume of 12 ml
Study NCT06230614 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Colistin 1 MU in normal saline 2 ml
Description: Colistin 1 MU diluted in normal saline 2 ml, total volume of 12 ml
Study NCT06481254 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hawthorn Vinegar Group
Description: To routine oral mucositis treatment, patients with DM in the hawthorn vinegar group gargled with 1 tablespoon (10 cc) of diluted hawthorn vinegar (mixed with 40 cc water) for 1 minute 15-20 minutes before meals 3 times a day for 14 days.
Study NCT06481254 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Black Mulberry Syrup Group
Description: To routine oral mucositis treatment, patients with DM in the black mulberry syrup group pure black mulberry syrup for 1 minute 15-20 minutes before meals 3 times a day for 14 days.
Study NCT06481254 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Green Tea Group
Description: To routine oral mucositis treatment, patients with DM in the green tea group gargled with 50 cc green tea for 1 minute 15-20 minutes before meals 3 times a day for 14 days.
Study NCT04912674 — intervention group
Intervention type: DEVICE
Intervention: Symphony OCT System
Description: Surgical intervention will be patient specified by treating surgeon.
Study NCT06564636 — intervention group
Intervention type: DEVICE
Intervention: CATALYSTEM
Description: CATALYSTEM Cementless Primary Hip System for participants with Total Hip Arthroplasty
Study NCT04222335 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Blood samples
Description: Each participant will be followed-up regularly as part of the usual practice for imaging and medical consultations. During their visits, from inclusion (T0) to the end of study participation (T progression), each patient will have a blood sampling specifically for the research to analyze tumor DNA and circulating tumor cells: T0, T1month, T3 months, Tn months, T DNA C+, T progression.~This research does not include any other act or intervention specifically required for its purposes.
Study NCT04380038 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dupilumab Injectable Product
Description: Nasal inoculation, single dose 300 TCID50 in 1ml.
Study NCT04380038 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dupilumab Injectable Product
Description: Nasal inoculation, single dose 300 TCID50 in 1ml.
Study NCT04231266 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ManNAc
Description: Oral N-acetyl-D-mannosamine monohydrate (ManNAc)
Study NCT04231266 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT05087329 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Mindfulness Meditation
Description: Four week virtual mindfulness meditation course composed of four weekly group Zoom webinars during which participants will listen to a 15-20 minute pre-recorded meditation, facilitated by a study provider
Study NCT05330325 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Somapacitan
Description: Somapacitan will be administered subcutaneously (s.c.) once weekly using PDS290 pen-injector.
Study NCT05330325 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norditropin®
Description: Norditropin® will be administered s.c. once daily using FlexPro® pen-injector.
Study NCT06645652 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training in observational drawing
Description: * 6 weeks of online gallery browsing based on different topics~* Daily practice drawing from observation with training adding up to 1 hour a week~* Documenting progress and reflection writing
Study NCT06645652 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Arts engagement through digital galleries
Description: * 6 weeks of online gallery browsing based on different topics~* 2 hours of weekly activities consist of reading and navigating technology~* Reflection writing
Study NCT05529758 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internalized Weight Bias Intervention
Description: ACT-based programs and self-compassion have shown promise throughout research for lowering IWB (Berman et al., 2016; Levin et al., 2018; Lillis et al., 2009; Palmeira, Cunha, \& Pinto-Gouveia, 2017; Palmeira, Pinto-Gouveia, \& Cunha, 2017; Forbes et al., 2020). Therefore, using techniques from prior ACT- and self-compassion based programs, a weight bias reduction intervention will be administered. Session topics will include psychoeducation and coping for weight bias and internal weight bias, and these topics will be viewed through a self-compassionate and ACT-based lens (for example, participants may defuse from internal critical thoughts rather than challenge them). Sessions will also cover acceptance, cognitive defusion, mindfulness, committed action, and the dialectical behavioral therapy (DBT) DEARMAN skill.
Study NCT06646471 — intervention group
Intervention type: GENETIC
Group type: OTHER
Intervention: Bio-bank repository
Description: Blood samples taken during the screening phase prior to the first administration of systemic treatment and stored in a repository for a maximum duration of 10 years
Study NCT06646471 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Quality of Life (QoL)
Description: Collection of EORTC QoL questionnaires QLQ-F17, QLQ-LC13 and QLQ-ELD14:~* stage 3 non-operable/non-radiable, stage 4: at inclusion, 12 weeks, 6 months of treatment, first-line progression.~* operable stage 1 to 3b: at inclusion, end of neoadjuvant period before surgery post-operative baseline, at 6 months, at 12 months.~* radiable stages 3a to 3c: at inclusion, at the end of thoracic radiotherapy, at 6 months, at 12 months.
Study NCT06646471 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: G-Code
Description: G-CODE: Katz Autonomy Scale (ADL), Instrumental Activities of Daily Living questionnaire (IADL), Charlson score, mini GDS, mini COG, falls history, Timed Get Up and Go test, social environment.
Study NCT05105425 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: NUTRIOSE®
Description: After randomization (V2 visit), the subjects will consume per os, from V2 to V3, 1 sachet of 15g per day, in the morning, of active formula (NUTRIOSE®) during 4 weeks.~They will consume 1 sachet in the morning. Powder will have to be mixed with usual beverage of the subject (whatever the type of drink, cold or hot).
Study NCT05105425 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: GLUCIDEX® IT21 (Placebo)
Description: After randomization (V2 visit), the subjects will consume per os, from V2 to V3, 1 sachet of 15g per day, in the morning, of placebo during 4 weeks.~They will consume 1 sachet in the morning. Powder will have to be mixed with usual beverage of the subject (whatever the type of drink, cold or hot).
Study NCT05363098 — intervention group
Intervention type: OTHER
Intervention: Mechanically ventilated neurosurgical patients
Description: Observational study where respiratory variables and intracranial pressure will be measured during assisted mechanical ventilation. No intervention is planned.
Study NCT06666023 — intervention group
Intervention type: DEVICE
Intervention: Device
Description: Use of the device in groups to test its ability to diagnose infections.
Study NCT06668792 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCD-248
Description: subcutaneously
Study NCT06664099 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: One Anastomosis Gastric Bypass (150 cm from Duodenojejunal Junction)
Description: This intervention involves performing a One Anastomosis Gastric Bypass surgery with the bypassed length of the small intestine set at 150 centimeters from the duodenojejunal junction. This shorter limb length is designed to achieve weight loss while potentially reducing the risk of nutritional deficiencies. The procedure is performed laparoscopically, with the stomach divided to create a gastric tube attached to a loop of the small intestine. Postoperative outcomes will include assessments of weight loss, total weight loss percentage, excess weight loss percentage, and nutritional markers such as albumin, calcium, and iron.
Study NCT06664099 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: One Anastomosis Gastric Bypass (170 cm from Duodenojejunal Junction)
Description: This intervention involves performing a One Anastomosis Gastric Bypass surgery with a bypassed length of 170 centimeters from the duodenojejunal junction, offering an intermediate limb length. This distance is intended to balance weight loss effectiveness with moderate risks of nutritional deficiencies. The laparoscopic procedure involves creating a gastric tube attached to a segment of the small intestine, bypassing the proximal portion. Outcomes monitored postoperatively include weight loss, percentage of total and excess weight loss, and nutritional parameters such as albumin, calcium, and iron levels.
Study NCT06664099 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: One Anastomosis Gastric Bypass (200 cm from Duodenojejunal Junction)
Description: This intervention consists of performing a One Anastomosis Gastric Bypass with the bypass length set at 200 centimeters from the duodenojejunal junction. This longer bypass length is designed to maximize weight loss outcomes but may carry a higher risk of nutritional deficiencies. The procedure is done laparoscopically, where the stomach is divided, creating a tube that is joined to the small intestine at the specified length. Postoperative assessments will focus on weight loss effectiveness, total and excess weight loss percentages, and the risk of nutritional deficiencies by measuring markers such as albumin, calcium, and iron.
Study NCT06594133 — intervention group
Intervention type: DRUG
Intervention: Antibiotic Treatment
Description: For lung transplant recipients with Nocardia infection, the treatment regimen could include:~Sulfamethoxazole/Trimethoprim (Bactrim): 800 mg/160 mg orally or intravenously twice daily for at least 6 months.~Imipenem: 500 mg intravenously every 6 hours for severe cases. Monitoring: Regular monitoring of blood levels of the drug to avoid toxicity and adjust doses accordingly.
Study NCT05477407 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Switch from an INSTI-based regimen to the non INSTI-based regimen combining TDF/3TC/Doravirine
Description: Each patient will be evaluated with an adipose tissue biopsy performed before (D0) and after a 48 week switch (W48) from an INSTI-based regimen to the non INSTI-based regimen combining TDF/3TC/Doravirine (Delstrigo®)